FDA Uses Rats to Prove Your Baby Formula Works
Published Date: 5/22/2026
Notice
Summary
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
FDA guidance helps formula makers pass PER studies
The FDA published guidance on May 22, 2026 that explains how infant formula manufacturers and contract laboratories should design, conduct, evaluate, and report Protein Efficiency Ratio (PER) rat bioassay studies under AOAC Official Method 960.48 to show a new infant formula meets the quality factor of sufficient biological quality of protein.
Technical rules: diet matching and method changes
The guidance finalizes ‘‘appropriate modifications’’ to AOAC Method 960.48, including recommendations to match compositions of test and reference PER study diets to within 20 percent above or below and to delete a prior recommendation for an optional casein reference group with matched sulfur amino acid concentrations.
Guidance aims to support formula supply resilience
FDA states the guidance will help ensure infant formula products meet regulatory requirements and 'will contribute to ensuring a more resilient infant formula supply.' The guidance was announced on May 22, 2026.
FDA signals future validation and alternatives talk
The guidance notes FDA anticipates future discussions about validation data for PER modifications and 'considering alternative methods besides the PER method,' including non-animal methods.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2026-10283 — Order Granting Additional Directors and Officers of Certain Foreign Private Issuers an Exemption From the Filing Requirements of Section 16(a) of the Exchange Act
The SEC is giving more foreign company leaders from Australia, India, and Singapore a break from some tricky paperwork rules. If these companies meet certain local rules, their directors and officers won’t have to file certain reports under Section 16(a) of the Exchange Act. This change starts right away and helps these leaders save time and avoid extra costs.
Next: 2026-10285 — New Postal Products
The Postal Regulatory Commission is reviewing new deals the Postal Service wants to add or change for competitive mail products. If you use or rely on these postal services, now’s your chance to share your thoughts before the Commission makes a decision. Keep an eye out for deadlines to comment and possible changes that might affect prices or services soon!